David Schaer

3.7k total citations · 1 hit paper
45 papers, 2.3k citations indexed

About

David Schaer is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, David Schaer has authored 45 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 29 papers in Immunology and 8 papers in Molecular Biology. Recurrent topics in David Schaer's work include Cancer Immunotherapy and Biomarkers (24 papers), Immunotherapy and Immune Responses (21 papers) and Immune Cell Function and Interaction (12 papers). David Schaer is often cited by papers focused on Cancer Immunotherapy and Biomarkers (24 papers), Immunotherapy and Immune Responses (21 papers) and Immune Cell Function and Interaction (12 papers). David Schaer collaborates with scholars based in United States, United Kingdom and Germany. David Schaer's co-authors include Jedd D. Wolchok, Taha Merghoub, Michael Kalos, Alan B. Frey, Mythili Koneru, Adam D. Cohen, Alan N. Houghton, Pat Zanzonico, Andrew Burns and Oula Peñate Medina and has published in prestigious journals such as Journal of Clinical Investigation, Nature Medicine and The Journal of Experimental Medicine.

In The Last Decade

David Schaer

44 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma

2011 504 citations David Schaer, Jedd D. Wolchok et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Schaer United States	19	1.3k	1.2k	481	321	257	45	2.3k
Haidong Tang China	13	972 0.7×	930 0.8×	387 0.8×	584 1.8×	128 0.5×	25	1.9k
Michael F. Cuccarese United States	9	1.1k 0.8×	635 0.5×	520 1.1×	692 2.2×	277 1.1×	11	1.8k
Sean P. Arlauckas United States	12	1.4k 1.1×	694 0.6×	851 1.8×	613 1.9×	207 0.8×	17	2.3k
Yu Han United States	28	1.3k 1.0×	1.1k 0.9×	987 2.1×	686 2.1×	403 1.6×	55	3.2k
Meenal Datta United States	17	663 0.5×	765 0.7×	569 1.2×	956 3.0×	170 0.7×	42	2.6k
Lydia Koenig United States	10	939 0.7×	1.2k 1.0×	456 0.9×	185 0.6×	199 0.8×	14	1.9k
Christopher Garris United States	20	2.0k 1.5×	1.1k 1.0×	1.1k 2.4×	778 2.4×	237 0.9×	33	3.3k
Peter M. Ferguson Australia	21	473 0.4×	666 0.6×	477 1.0×	187 0.6×	134 0.5×	68	1.5k
Felix B. Salazar United States	18	605 0.5×	700 0.6×	371 0.8×	516 1.6×	146 0.6×	29	1.6k
G‐One Ahn South Korea	24	666 0.5×	868 0.7×	838 1.7×	337 1.0×	104 0.4×	44	2.4k

Countries citing papers authored by David Schaer

Since Specialization

Citations

This map shows the geographic impact of David Schaer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Schaer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Schaer more than expected).

Fields of papers citing papers by David Schaer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Schaer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Schaer. The network helps show where David Schaer may publish in the future.

Co-authorship network of co-authors of David Schaer

This figure shows the co-authorship network connecting the top 25 collaborators of David Schaer. A scholar is included among the top collaborators of David Schaer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Schaer. David Schaer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yap, Timothy A., Atish D. Choudhury, Erika Hamilton, et al.. (2024). PF-06952229, a selective TGF-β-R1 inhibitor: preclinical development and a first-in-human, phase I, dose-escalation study in advanced solid tumors. ESMO Open. 9(9). 103653–103653. 9 indexed citations

Morfouace, Marie, Laurence Buisseret, Benjamin Besse, et al.. (2023). 195P IMMUcan: Toward a better understanding of the tumor microenvironment to inform precision oncology approaches. Immuno-Oncology Technology. 20. 100654–100654.

Li, Yanxia, Nelusha Amaladas, Jason R. Manro, et al.. (2022). Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor models. PLoS ONE. 17(7). e0268244–e0268244. 11 indexed citations

Zappasodi, Roberta, Cynthia A. Sirard, Yanyun Li, et al.. (2019). Rational design of anti-GITR-based combination immunotherapy. Nature Medicine. 25(5). 759–766. 177 indexed citations

Zappasodi, Roberta, Cynthia A. Sirard, Yanyun Li, et al.. (2019). Abstract 2711: Rational combination of GITR agonism with PD-1 blockade. Immunology. 2711–2711. 1 indexed citations

Autio, Karen A., Christopher A. Klebanoff, David Schaer, et al.. (2019). Phase 1 study of LY3022855, a colony-stimulating factor-1 receptor (CSF-1R) inhibitor, in patients with metastatic breast cancer (MBC) or metastatic castration-resistant prostate cancer (MCRPC).. Journal of Clinical Oncology. 37(15_suppl). 2548–2548. 16 indexed citations

Holmgaard, Rikke, David Schaer, Yanxia Li, et al.. (2018). Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade. Journal for ImmunoTherapy of Cancer. 6(1). 47–47. 267 indexed citations

Dowlati, Afshin, Hope S. Rugo, R. Donald Harvey, et al.. (2017). A phase I study of LY3022855, a colony-stimulating factor-1 receptor (CSF-1R) inhibitor, in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology. 35(15_suppl). 2523–2523. 7 indexed citations

Schaer, David, Yanxia Li, Stephen Castaneda, et al.. (2015). Targeting the TGFβ pathway with galunisertib, a TGFβRI SMI, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint inhibition. Journal for ImmunoTherapy of Cancer. 3(Suppl 2). P402–P402. 1 indexed citations

10.

Schaer, David, Daniel Hirschhorn-Cymerman, & Jedd D. Wolchok. (2014). Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy. Journal for ImmunoTherapy of Cancer. 2(1). 7–7. 93 indexed citations

11.

Schaer, David, Sadna Budhu, Cailian Liu, et al.. (2013). GITR Pathway Activation Abrogates Tumor Immune Suppression through Loss of Regulatory T-cell Lineage Stability. Cancer Immunology Research. 1(5). 320–331. 121 indexed citations

12.

Schaer, David, et al.. (2012). Modulation of GITR for cancer immunotherapy. Current Opinion in Immunology. 24(2). 217–224. 110 indexed citations

13.

Schaer, David, Yongbiao Li, Taha Merghoub, et al.. (2011). Detection of Intra-Tumor Self Antigen Recognition during Melanoma Tumor Progression in Mice Using Advanced Multimode Confocal/Two Photon Microscope. PLoS ONE. 6(6). e21214–e21214. 12 indexed citations

14.

Cohen, Adam D., David Schaer, Cailian Liu, et al.. (2010). Agonist Anti-GITR Monoclonal Antibody Induces Melanoma Tumor Immunity in Mice by Altering Regulatory T Cell Stability and Intra-Tumor Accumulation. PLoS ONE. 5(5). e10436–e10436. 199 indexed citations

15.

Avogadri, Francesca, Jianda Yuan, Arvin Yang, David Schaer, & Jedd D. Wolchok. (2010). Modulation of CTLA-4 and GITR for Cancer Immunotherapy. Current topics in microbiology and immunology. 344. 211–244. 21 indexed citations

16.

Koneru, Mythili, Ngozi Monu, David Schaer, Justine A. Barletta, & Alan B. Frey. (2006). Defective Adhesion in Tumor Infiltrating CD8+ T Cells. The Journal of Immunology. 176(10). 6103–6111. 28 indexed citations

17.

Entenberg, David, et al.. (2006). Multimodal microscopy of immune cells and melanoma for longitudinal studies. Proceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE. 6081. 60810A–60810A. 5 indexed citations

18.

Koneru, Mythili, et al.. (2005). Defective Proximal TCR Signaling Inhibits CD8+ Tumor-Infiltrating Lymphocyte Lytic Function. The Journal of Immunology. 174(4). 1830–1840. 61 indexed citations

19.

Radoja, Saša, Masanao Saio, David Schaer, et al.. (2001). CD8+ Tumor-Infiltrating T Cells Are Deficient in Perforin-Mediated Cytolytic Activity Due to Defective Microtubule-Organizing Center Mobilization and Lytic Granule Exocytosis. The Journal of Immunology. 167(9). 5042–5051. 128 indexed citations

20.

Sengupta, S. K. & David Schaer. (1978). The interaction of 7-substituted actinomycin D analogs with DNA. Biochimica et Biophysica Acta (BBA) - Nucleic Acids and Protein Synthesis. 521(1). 89–100. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact